Effects of a superoxide dismutase mimetic on biomarkers of lung angiogenesis and alveolarization during hyperoxia with intermittent hypoxia

American Journal of Translational Research

Volumn 5, Issue 6, 2013, Pages 594-607

  Chang, Michael ^a,b   Bany Mohammed, Fayez ^a   Cristina Kenney, M ^c   Beharry, Kay D ^d  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b MILLER CHILDREN S HOSPITAL   (United States)

^c UNIVERSITY OF CALIFORNIA   (United States)

^d SUNY DOWNSTATE MEDICAL CENTER   (United States)

Author keywords

Antioxidants; Hyperoxia; Intermittent hypoxia; Matrix metalloproteinases; Tissue inhibitor of metalloproteinase

Indexed keywords

GELATINASE A; GELATINASE B; PLACEBO; REACTIVE OXYGEN METABOLITE; SUPEROXIDE DISMUTASE; TISSUE INHIBITOR OF METALLOPROTEINASE 1; VASCULOTROPIN; VASCULOTROPIN RECEPTOR 1;

ANGIOGENESIS; ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; BODY WEIGHT; CONTROLLED STUDY; DRUG DOSE COMPARISON; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HYPEROXIA; INTERMITTENT HYPOXIA; LUNG DYSPLASIA; MALE; NEWBORN; NONHUMAN; RAT;

RATTUS;

EID: 84885073459     PISSN: None     EISSN: 19438141     Source Type: Journal    
DOI: None     Document Type: Article

References (64)

1. Coalson JJ. Pathology of new bronchopulmonary dysplasia. Semin Neonatol 2003; 8: 73-81.
2. De Paepe ME, Mao Q, Powell J, Rubin SE, DeKoninck P, Appel N, Dixon M, Gundogan F. Growth of pulmonary microvasculature in ventilated preterm infants. Am J Respir Crit Care Med 2006; 173: 204-211.
3. Ryan RM, Ahmed Q, Lakshminrusimha S. Inflammatory mediators in the immunobiology of bronchopulmonary dysplasia. Clinic Rev Allerg Immunol 2008; 34: 174-190.
4. Bhatt AJ, Pryhuber GS, Huyck H, Watkins RH, Metlay LA, Maniscalco WM. Disrupted pulmonary vasculature and decreased vascular endothelial growth factor, Flt-1, and TIE-2 in human infants dying with bronchopulmonary dysplasia. Am J Respir Crit Care Med 2001; 164: 1971-1980.
5. Coalson JJ, Winter V, DeLemos RA. Decreased alveolarization in baboon survivors with bronchopulmonary dysplasia. Am J Respir Crit Care Med 1995; 152: 640-646.
6. Davis JM. Role of oxidant injury in the pathogenesis of neonatal lung disease. Acta Paediatr Suppl 2002; 437: 23-25.
7. Saugstad OD. Bronchopulmonary dysplasiaoxidative stress and antioxidants. Semin Neonatol 2003; 8: 39-49.
8. Auten RL, Davis JM. Oxygen toxicity and reactive oxygen species: the devil is in the details. Pediatr Res 2009; 66: 121-127.
9. Rogers LK, Tipple TE, Nelin LD, Welty SE. Differential responses in the lungs of newborn mouse pups exposed to 85% or >95% oxygen. Pediatr Res 2009; 65: 33-38.
10. Jobe AH, Kallapur SG. Long term consequences of oxygen therapy in the neonatal period. Semin Fetal Neonatal Med 2010; 15: 230-235.
11. 2-, TGF-β, and VEGF production by macrophages. Free Radic Res 2007; 41: 8-14.
12. Ratner V, Slinko S, Utkina-Sosunova I, Starkov A, Polin RA, Ten VS. Hypoxic stress exacerbates hyperoxia-induced lung injury in a neonatal mouse model of bronchopulmonary dysplasia. Neonatology 2009; 95: 299-305.
13. Jakkula M, Le Cras TD, Gebb S, Hirth KP, Tuder RM, Voelkel NF, Abman SH. Inhibitoin of angiogenesis decreases alveolarization in the developing rat lung. Am J Physiol Lung Cell Mol Physiol 2000; 279: L600-L607.
14. Remesal A, Pedraz C, San Feliciano L, Ludeña D. Pulmonary expression of vascular endothelial growth factor (VEGF) and alveolar septation in a newborn rat model exposed to acute hypoxia and recovered under conditions of air or hyperoxia. Histol Histopathol 2009; 24: 325-330.
15. Abman SH. Impaired vascular endothelial growth factor signaling in the pathogenesis of neonatal pulmonary vascular disease. Adv Exp Med Biol 2010; 661: 323-335.
16. Maniscalco WM, Watkins RH, Pryhuber GS, Bhatt A, Shea C, Huyck H. Angiogenic factors and alveolar vasculature: development and alterations by injury in very premature baboons. Am J Physiol Lung Cell Mol Physiol 2002; 282: L811-L823.
17. Hosford GE, Olson DM. Effects of hyperoxia on VEGF, its receptors, and HIF-2 in the newborn rat lung. Am J Physiol Lung Cell Mol Physiol 2003; 285: L161-L168.
18. Lassus P, Turanlahti M, Heikkilä P, Andersson LC, Nupponen I, Sarnesto A, Andersson S. Pulmonary vascular endothelial growth factor and Flt-1 in fetuses, in acute and chronic lung disease, and in persistent pulmonary hypertension of the newborn. Am J Respir Crit Care Med 2001; 164: 1981-1987.
19. Hasan J, Beharry KD, Valencia AM, Strauss A, Modanlou HD. Soluble vascular endothelial growth factor receptor 1 in tracheal aspirate fluid of preterm neonates at birth may be predictive of bronchopulmonary dysplasia/chronic lung disease. Pediatrics 2009; 123: 1541-1547.
20. Acarregui MJ, Penisten ST, Goss KL, Ramirez K, Snyder JM. Vascular endothelial growth factor gene expression in human fetal lung in vitro. Am J Respir Cell Mol Biol 1999; 20: 14-23.
21. Cederqvist K, Sorsa T, Tervahartiala T, Maisi P, Reunanen K, Lassus P, Andersson S. Matrix metalloproteinases-2, -8, and -9 and TIMP-2 in tracheal aspirates from preterm infants with respiratory distress. Pediatrics 2001; 108: 686-692.
22. Danan C, Jarreau PH, Franco ML, Dassieu G, Grillon C, Alsamad A, LaFuma C, Harf A, Delacourt C. Gelatinase activities in the airways of premature infants and development of bronchopulmonary dysplasia. Am J Physiol Lung Cell Mol Physiol 2002; 283: L1086-L1093.
23. Ekekezie II, Thibeault DW, Simon SD, Norberg M, Merrill JD, Ballard RA, Ballard PL, Truog WE. Low levels of tissue inhibitors of metalloproteinases with a high matrix metalloproteinase-9/tissue inhibitor of metalloproteinase-1 ratio are present in tracheal aspirate fluids of infants who develop chronic lung disease. Pediatrics 2004; 113: 1709-1714.
24. Davies PL, Spiller OB, Beeton ML, Maxwell NC, Remold-O'Donnell E, Kotecha S. Relationship of proteinases and proteinase inhibitors with microbial presence in chronic lung disease of prematurity. Thorax 2010; 65: 246-251.
25. Tambunting F, Beharry KD, Hartleroad J, Waltzman J, Stavitsky Y, Modanlou HD. Increased lung matrix metalloproteinase-9 levels in extremely premature baboons with bronchopulmonary dysplasia. Pediatr Pulmonol 2005; 39: 5-14.
26. Schulz CG, Sawicki G, Lemke RP, Roeten BM, Schulz R, Cheung P. MMP-2 and MMP-9 and their tissue inhibitors in the plasma of preterm and term neonates. Pediatr Res 2004; 55: 794-801.
27. Pardo A, Selman M, Ridge K, Barrios R, Sznajder JI. Increased expression of gelatinases and collagenase in rat lungs exposed to 100% oxygen. Am J Respir Crit Care Med 1996; 154: 1067-1075.
28. Schock BC, Sweet DG, Ennis M, Warner JA, Young IA, Halliday HL. Oxidative stress and increased type-IV collagenase levels in bronchoalveolar lavage fluid from newborn babies. Pediatr Res 2001; 50: 29-33.
29. Fukunaga S, Ichiyama T, Maeba S, Okuda M, Nakata M, Sugino N, Furukawa S. MMP-9 and TIMP-1 in the cord blood of premature infants developing BPD. Pediatr Pulmonol 2009; 44: 267-272.
30. Pardo A, Barrios R, Maldonado V, Meléndez J, Pérez J, Ruiz V, Segura-Valdez L, Sznajder JI, Selman M. Gelatinases A and B are up-regulated in rat lungs by subacute hyperoxia. Am J Pathol 1998; 153: 833-844.
31. Chetty A, Cao G, Severgnin M, Simon A, Warburton R, Nielsen HC. Role of matrix metalloprotease-9 in hyperoxic injury in developing lung. Am J Physiol Lung Cell Mol Physiol 2008; 295: L584-L592.
32. Lukkarinen H, Hogmalm A, Lappalainen U, Bry K. Matrix metalloproteinase-9 deficiency worsens lung injury in a model of bronchopulmonary dysplasia. Am J Respir Cell Mol Biol 2009; 41: 59-68.
33. Autor AP, Frank L, Roberts RJ. Developmental characteristics of pulmonary superoxide dismutase: relationship to idiopathic respiratory distress syndrome. Pediatr Res 1976; 10: 154-158.
34. Frank L, Sosenko IRS. Prenatal development of lung antioxidant enzymes in four species. J Pediatr 1987; 110: 106-110.
35. Morton RL, Das KC, Guo X, Iklé DN, White CW. Effect of oxygen on lung superoxide dismutase activities in premature baboons with bronchopulmonary dysplasia. Am J Physiol Lung Cell Mol Physiol 1999; 276: L64-L74.
36. Asikainen TM, Heikkilä P, Kaarteenaho-Wiik R, Kinnula VL, Raivio KO. Cell-specific expression of manganese superoxide dismutase protein in the lungs of patients with respiratory distress syndrome, chronic lung disease, or persistent pulmonary hypertension. Pediatr Pulmonol 2001; 32: 193-200.
37. Wispe JR, Warner BB, Clark JC, Dey CR, Neuman J, Glasser SW, Crapo JD, Chang L, Jeffrey AW. Human Mn-superoxide dismutase in pulmonary epithelial cells of transgenic mice confers protection from oxygen injury. J Biol Chem 1992; 267: 23937-23941.
38. Wilborn AM, Evers LB, Canada AT. Oxygen toxicity to the developing lung of the mouse: role of reactive oxygen species. Pediatr Res 1996; 40: 225-232.
39. Ilizarov AM, Koo H, Kazzaz JA, Mantell LL, Li Y, Bhapat R, Pollack S, Horowitz S, Davis JM. Overexpression of manganese superoxide dismutase protects lung epithelial cells against oxidant injury. Am J Respir Cell Mol Biol 2001; 24: 436-441.
40. Chang LL, Subramaniam M, Yoder BA, Day BJ, Ellison MC, Sunday ME, Crapo JD. A catalytic antioxidant attenuates alveolar structural remodeling in bronchopulmonary dysplasia. Am J Respir Crit Care Med 2003; 167: 57-64.
41. Davis JM, Parad RB, Michele T, Allred E, Price A, Rosenfeld W. Pulmonary outcome at 1 year corrected age in premature infants treated at birth with recombinant human CuZn superoxide dismutase. Pediatrics 2003; 111: 469-476.
42. Salvemini D, Cuzzocrea S. Therapeutic potential of superoxide dismutase mimetics as therapeutic agents in critical care medicine. Crit Care Med 2003; 31: S29-S38.
43. Coleman RJ, Beharry KD, Brock RS, Abad-Santos P, Abad-Santos M, Modanlou HD. Effects of brief, clustered versus dispersed hypoxic episodes on systemic and ocular growth factors in a rat model of oxygen-induced retinopathy. Pediatr Res 2008; 64: 50-5.
44. Melov S, Ravenscroft J, Malik S, Gill MS, Walker DW, Clayton PE, Wallace DC, Malfroy B, Doctrow SR, Lithgow GJ. Extension of life-span with superoxide dismutase/catalase mimetics. Science 2000; 289: 1567-1569.
45. Melov S, Doctrow SR, Schneider JA, Haberson J, Patel M, Coskun PE, Huffman K, Wallace DC, Malfroy B. Lifespan extension and rescue of spongiform encephalopathy in superoxide dismutase 2 nullizygous mice treated with superoxide dismutase-catalase mimetics. J Neurosci 2001; 21: 8348-8353.
46. Landry JS, Menzies D. Occurrence and severity of bronchopulmonary dysplasia and respiratory distress syndrome after a preterm birth. Paediatr Child Health 2011; 16: 399-403.
47. Subramanian S, El-Mohandes A, Dhanireddy R, Koch MA. Association of bronchopulmonary dysplasia and hypercarbia in ventilated infants with birthweights of 500-1499 g. Matern Child Health J 2011; 15: S17-S26.
48. Martin RJ, Di Fiore JM, Macfarlane PM, Wilson CG. Physiologic basis for intermittent hypoxic episodes in preterm infants. Adv Exp Med Biol 2012; 758: 351-358.
49. Martin RJ, Wang K, Köroǧlu Ö, Di Fiore J, Kc P. Intermittent hypoxic episodes in preterm infants: Do they Matter? Neonatology 2011; 100: 303-310.
50. Haworth SG, Hislop AA. Lung development the effects of chronic hypoxia. Semin Neonatol 2003; 8: 1-8.
51. Brock RS, Gebrekristos BH, Kuniyoshi KM, Modanlou HD, Falcao MC, Beharry KD. Biomolecular effects of JB1 (an IGF-I peptide analog) in a rat model of oxygen-induced retinopathy. Pediatr Res 2011; 69: 35-41.
52. Freeman BA, Topolosky MK, Crapo JD. Hyperoxia increases oxygen radical production in rat lung homogenates. Arch Biochem Biophys 1982; 216: 477-484.
53. Ratner V, Slinko S, Utkino-Sosunova I, Starkov A, Polin RA, Ten VS. Hypoxic Stress exacerbates hyperoxia-induced lung injury in a neonatal mouse model of Bronchopulmonary dysplasyia. Neonatology 2009; 95: 299-305.
54. Asikainen TM, White CW. Pulmonary antioxidant defenses in the preterm newborn with respiratory distress and bronchopulmonary dysplasia in evolution: implication for antioxidant therapy. Antioxid Redox Signal 2004; 6: 155-167.
55. Valko M, Leibfritz D, Moncol J, Cronin MTD, Mazur M, Telser J. Free radicals and antioxidants in normal physiological functions and human disease. Int J Biochem Cell Biol 2007; 39: 44-84.
56. Tschanz SA, Makanya AN, Haenni B, Burri PH. Effects of neonatal high-dose shrot-term glucocorticoid treatment on the lung: A morphologic and morphometric study in the rat. Pediatr Res 2003; 53: 72-80.
57. Gardner TJ, Stewart JR, Casale AS, Downey JM, Chambers DE. Reduction of myocardial ischemic injury with oxygen derived free radical scavengers. Surgery 1983; 94: 423-427.
58. Shima DT, Deutsch U, D'Amore PA. Hypoxic induction of vascular endothelial growth factor (VEGF) in human epithelial cells is mediated by increases in mRNA stability. FEBS Lett 1995; 370: 203-208.
59. Oury TD, Thakker K, Menache M, Chang L, Crapo JD, Day BJ. Attenuation of bleomycin-induced pulmonary fibrosis by a catalytic antioxidant metalloporphyrin. Am J Respir Cell Mol Biol 2001; 25: 164-169.
60. Cho M, Hunt TK, Hussain MZ. Hydrogen peroxide stimulates macrophage vascular endothelial growth factor release. Am J Physiol Heart Circ Physiol 2001; 280: H2357-H2363.
61. Le Cras TD, Spitzmiller RE, Albertine KH, Greenberg JM, Whitsett JA, Akeson AL. VEGF causes pulmonary hemorrhage, hemosiderosis, and air space enlargement in neonatal mice. Am J Physiol Lung Cell Mol Physiol 2004; 287: L134-L142.
62. Ambalavanan N, Nicola T, Li P, Bulger A, Murphy-Ullrich J, Oparil S, Chen YF. Role of matrix metalloproteinase-2 in newborn mouse lungs under hypoxic conditions. Pediatr Res 2008; 63: 26-32.
63. Dik WA, van Kaam AH, Dekker T, Naber BA, Janssen DJ, Krron AA, Zimmermann LJ, Versnel MA, Lutter R. Early increased levels of matrix metalloproteinase-9 in neonates recovering from respiratory distress syndrome. Biol Neonate 2006; 89: 6-14.
64. Gurjar MV, Deleon J, Sharma RV, Bhalla RC. Role of reactive oxygen species in IL-1 betastimulated sustained ERK activation and MMP-9 induction. Am J Physiol Heart Circ Physiol 2001; 281: H2568-H2574.